- £127.34m
- £110.04m
- £27.17m
- 44
- 16
- 63
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.85 | ||
| Price to Tang. Book | 2.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.76% | ||
| Return on Equity | -38.59% | ||
| Operating Margin | -96.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | 0.01 | 9.43 | 25.16 | 27.17 | 32.71 | 40.59 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Creo Medical Group plc is a medical device company. The Company is focused on the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. It is engaged in research, development and distribution of electrosurgical medical devices relating to the field of surgical endoscopy. The Company has developed the CROMA powered by Kamaptive full-spectrum adaptive technology, which provides optimized surgical capability and patient outcomes. The Kamaptive is a seamless, intuitive integration of multi-modal energy sources. Its CROMA delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused high frequency microwave (MW) energy for controlled coagulation and ablation via a single accessory port. This technology, combined with its range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 12th, 2016
- Public Since
- December 9th, 2016
- No. of Employees
- 279
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 361,251,418
- Address
- Unit 2 Beaufort Park,, Beaufort Park Way, CHEPSTOW, NP16 5UH
- Web
- https://creomedical.com/
- Phone
- +44 1291606005
- Auditors
- PricewaterhouseCoopers LLP
Latest News for CREO
Upcoming Events for CREO
Full Year 2023 Creo Medical Group PLC Earnings Release
Creo Medical Group PLC Annual Shareholders Meeting
Half Year 2024 Creo Medical Group PLC Earnings Release
Similar to CREO
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Advanced Oncotherapy
London Stock Exchange
Angle
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 19:06 UTC, shares in Creo Medical are trading at 35.25p. This share price information is delayed by 15 minutes.
Shares in Creo Medical last closed at 35.25p and the price had moved by +30.56% over the past 365 days. In terms of relative price strength the Creo Medical share price has outperformed the FTSE All Share Index by +28.3% over the past year.
The overall consensus recommendation for Creo Medical is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Creo Medical does not currently pay a dividend.
Creo Medical does not currently pay a dividend.
Creo Medical does not currently pay a dividend.
To buy shares in Creo Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 35.25p, shares in Creo Medical had a market capitalisation of £127.34m.
Here are the trading details for Creo Medical:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CREO
Based on an overall assessment of its quality, value and momentum Creo Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Creo Medical is 99.50p. That is 182.27% above the last closing price of 35.25p.
Analysts covering Creo Medical currently have a consensus Earnings Per Share (EPS) forecast of -£0.06 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Creo Medical. Over the past six months, its share price has underperformed the FTSE All Share Index by -5.3%.
As of the last closing price of 35.25p, shares in Creo Medical were trading -0.04% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Creo Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 35.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Creo Medical's directors